Clinical data from breast cancer patients indicate that high expression of the RNA helicase DDX3 is significantly associated with shortened overall survival and bone metastasis; consequently, small-molecule inhibitors targeting DDX3X are being explored as therapeutic agents for breast cancer bone metastasis (Winnard et al., 2024). Here, DDX3X is linked to breast cancer.